Oseltamivir Phosphate For Oral Suspension

Oseltamavir PFOS

Oseltamivir is an antiviral medication used to treat and prevent influenza (flu) caused by influenza A and B viruses.

What does “PFOS” mean?

In medication labeling, PFOS usually refers to Oseltamivir Phosphate — the phosphate salt form of oseltamivir.

It improves the drug’s stability and absorption in the body.

⚠️ It is not related to the chemical pollutant PFOS (perfluorooctanesulfonic acid). In this context, it simply indicates the pharmaceutical salt form.

How it works

Oseltamivir is a neuraminidase inhibitor.

It blocks the influenza virus enzyme neuraminidase, which prevents the virus from spreading to healthy cells.

Best results occur when started:

Within 48 hours of flu symptom onset.

Common Uses

✔ Treatment of flu symptoms

✔ Prevention after exposure (e.g., family member with flu)

✔ Used in adults and children (dose depends on age/weight)

Typical Adult Dose

Treatment: 75 mg twice daily for 5 days

Prevention: 75 mg once daily for 7–10 days

Always follow a doctor’s prescription.

Possible Side Effects

Most common:

Nausea

Vomiting

Headache

Rare but serious:

Allergic reactions

Confusion or unusual behavior (mostly reported in children)

Important Notes

It does not cure the flu instantly.

It does not replace flu vaccination.

It is ineffective against common cold viruses.

Basic Information as per USP

Molecular formula (free base): C₁₆H₂₈N₂O₄
Molecular formula (phosphate salt – PFOS form marketed): C₁₆H₂₈N₂O₄ · H₃PO₄
Molecular weight (free base): 312.4 g/mol
Drug class: Neuraminidase inhibitor (antiviral)

Key Structural Features

Cyclohexene ring core
Ethyl ester group
Primary amine (–NH₂)
Secondary amine
Ether linkage
Acetamido group

The marketed form is oseltamivir phosphate, which is the phosphate salt of the active oseltamivir base.

Oseltamavir PFOS in usp

Oseltamivir phosphate in United States Pharmacopeia (USP)

In the USP–NF, the official monograph name is:

Oseltamivir Phosphate

It is listed as the phosphate salt of oseltamivir (not “PFOS” — the correct abbreviation in pharmacopeial context is simply oseltamivir phosphate).

📌 USP Monograph Key Information

Official Name: Oseltamivir Phosphate

Category: Antiviral agent

Dosage forms covered:

Capsules

Powder for Oral Suspension

🧪 USP Description (Summary)

Chemical name:

Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate

Molecular formula:

C₁₆H₂₈N₂O₄ · H₃PO₄

Molecular weight:

410.40 g/mol

Structure: Oseltamivir base + phosphoric acid (1:1 salt)

🔬 USP Identification Tests Typically Include

Infrared (IR) spectroscopy

HPLC retention time comparison with USP Reference Standard

Phosphate identification test

📊 USP Assay Method (General)

Technique: HPLC

Acceptance criteria: Typically 98.0% – 102.0% (on anhydrous basis)

Impurities controlled per USP related substances test

📦 USP Reference Standard

USP provides:

Oseltamivir Phosphate RS

Used for:

Assay

Related substances

System suitability testing

Full USP monograph assay conditions (mobile phase, column, wavelength)

Impurity limits

Dissolution specifications for capsules

Comparison with Ph. Eur. or BP

Comments

Sterility Testing by Direct Inoculation Method

Sterility Testing by Direct Inoculation Method Direct Inoculation Method Learn the procedure for sterility test for sterile pharmaceutical products by direct inoculation method. 1.0 Objective : To lay down Standard Operating Procedure is to provide guidelines for sterility testing by Direct Inoculation Method. 2.0 Scope This procedure is applicable for the products manufactured at the location which can not be tested by Membrane Filtration Method. 3.0 Responsibility Implementation: Microbiologist 4.0 Accountability Execution: Manager - QC Review & Approval : AGM - QA / QC Procedure Direct Inoculation Method Sample for Finished Products: Collect the samples to be tested for sterility. Out of the whole sample, randomly select 20 articles of each lot of batch for both LVP and SVP t erminal ly sterilized products and for aseptically filled products. Sample for Intermediates: Randomly collect 16 pre-sterilized bottle samples to be tested for sterility from LVP bot...

SOP for Washing of HPLC Column After Use

SOP for Washing of HPLC Column After Use Standard operating procedure to wash the HPLC column after analysis. 1.0 OBJECTIVE To clean the column thoroughly after its each use to avoid any interference on repeated usage. 2.0 SCOPE This procedure is applicable for different groups of H.P.L.C columns used in Quality Control laboratory. 3.0 RESPONSIBILITY 2.1 Doing: Technical Assistant 2.2 Checking: Executive /Manager 4.0 ACCOUNTABILITY Head of the Department 5.0 PROCEDURE 5.1 For C18, C8, C6, Phenyl, (CN, Amine, Silica column.:) 5.1.1 Wash the column with the solvent which is use in individual product mobile phase preparation. eg. suppose water is use in mobile phase preparation then wash the column with water. 5.1.2 Allow the minimum 30 ml washing medium to flow through the column. 5.1.3 Disconnect the column from the HPLC unit and store in an allocated place. 5.2 For Protein pack column: 5.2.1 Wash the column with minimum 30 ml of 2.5 M acetic acid. 5.2.4 Disconnect the column from ...

High-Efficiency Particulate Air (HEPA) and Its Significance in Sterile Pharmaceutical Preparations

High-Efficiency Particulate Air (HEPA) and Its Significance in Sterile Pharmaceutical Preparations Everything about HEPA filters as pore size, leak test, DOP test and importance in sterile pharmaceutical manufacturing and analysis. HEPA filter integrity should be maintained to ensure aseptic conditions. Leak testing should be performed at installation to detect integrity breaches around the sealing gaskets, through the frames, or through various points on the filter media. Thereafter, leak tests should be performed at suitable time intervals for HEPA filters in the aseptic processing facility. For example, such testing should be performed twice a year in the aseptic processing room. Additional testing may be appropriate when air quality is found to be unacceptable, facility renovations might be the cause of disturbances to ceiling or wall structures, or as part of an investigation into a media fill or drug product sterility failure. Among the filters that should be leak tested ar...

Media Fill Test for Sterile API Manufacturing Process

Media Fill Test for Sterile API Manufacturing Process Know about the process simulation test for the active pharmaceutical ingredient (API) manufacturing process. Media fill test is done to verify the sterility of the sterile manufacturing process. Media fill validation for sterile API is different from the sterile formulation media fill. There are different processes in the sterile API manufacturing as filtration, crystallization, drying, milling etc. These all are different from the sterile formulation process where the sterile material is filled in sterile containers in aseptic conditions . Lactose powder is used in the process simulation. The whole media fill process is carried out in two phases 1) Wet Phase 2) Dry phase 1) Wet Phase: Non-sterile lactose powder is used in the wet phase. Wet phase simulates the liquid processing steps of the manufacturing process i.e. aseptic filtration of lactose solution from controlled area reactor to cryst...

Aseptic Filling Process (Media Fill) Validation Protocol in Sterile Pharmaceuticals

Aseptic Filling Process (Media Fill) Validation Protocol in Sterile Pharmaceuticals Validation of sterile manufacturing process by media fill validation test as per PICS guidelines for aseptic validation or aseptic process simulation. 1.0 OBJECTIVE 1.1 To define procedures for validating and maintaining the validation of all aseptic filling processes and qualification of the quality of the product by system/facility/equipment. 2.0 SCOPE 2.1 This procedure applies to all aseptically filled sterile products intended for human use. 3.0 RESPONSIBILITY 3.1 The Validation personnel coordinate the aseptic filling validation program and write the sterile media aseptic filling processes reports. 3.2 Manufacturing personnel the sterile media aseptic filling processes and performs the sterile media fills. 3.3 QA personnel perform the sampling and assist with the IPQA monitoring required for each sterile media fill. 3.4 QC personnel to perform the testing and assist with the monitoring required fo...

Pharmaceutical Guidelines

Search This Blog